Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $43.78B | $-3.48B | $-0.88 |
| 2024 | $46.61B | $-2.55B | $-0.65 |
| 2023 | $47.64B | $-2.94B | $-0.75 |
| 2022 | $50.74B | $4.15B | $1.06 |
| 2021 | $44.08B | $1.00B | $0.26 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.13 per share
Typical surprise +24.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.29 vs $0.23beat
- Tue, May 12$0.79 vs $0.64beat
- Wed, Mar 4$0.18 vs $0.18beat
- Wed, Nov 12$0.17 vs $0.13beat
- Wed, Aug 6$0.35 vs $0.25beat
- Wed, Mar 5$0.28 vs $0.28beat
Estimates and results for BAYRY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
BAYRYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·1d ago·Positive
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
View source ↗